Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brenda Weigel

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Human Pathology|May 14, 2013
Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcomaBridget Charbonneau, Rachel Isaksson Vogel, J Carlos Manivel, et al.
Pediatric Blood & Cancer|March 24, 2017
Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology GroupAbha A Gupta, Yueh-Yun Chi, James R Anderson, et al.
Pediatric Blood & Cancer|December 3, 2014
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology GroupLars M Wagner, Maryam Fouladi, Atif Ahmed, et al.
Pediatric Blood & Cancer|August 20, 2013
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology GroupBrenda Weigel, Suman Malempati, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium studyYael P Mossé, Emily Lipsitz, Elizabeth Fox, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2010
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancersMelissa A Geller, Sarah Cooley, Peter A Argenta, et al.
Neuro-Oncology|August 4, 2021
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group reportJack M Su, Lindsay B Kilburn, David B Mansur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium reportBrigitte C Widemann, Aerang Kim, Elizabeth Fox, et al.
Pediatric Blood & Cancer|April 5, 2013
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium studyTrent R Hummel, Lars Wagner, Charlotte Ahern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2012
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium reportJulia Glade Bender, Susan M Blaney, Scott Borinstein, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Human Pathology|May 14, 2013
Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcomaBridget Charbonneau, Rachel Isaksson Vogel, J Carlos Manivel, et al.
Pediatric Blood & Cancer|March 24, 2017
Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology GroupAbha A Gupta, Yueh-Yun Chi, James R Anderson, et al.
Pediatric Blood & Cancer|December 3, 2014
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology GroupLars M Wagner, Maryam Fouladi, Atif Ahmed, et al.
Pediatric Blood & Cancer|August 20, 2013
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology GroupBrenda Weigel, Suman Malempati, Joel M Reid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium studyYael P Mossé, Emily Lipsitz, Elizabeth Fox, et al.
Cancer Immunology, Immunotherapy : CII|September 8, 2010
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancersMelissa A Geller, Sarah Cooley, Peter A Argenta, et al.
Neuro-Oncology|August 4, 2021
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group reportJack M Su, Lindsay B Kilburn, David B Mansur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium reportBrigitte C Widemann, Aerang Kim, Elizabeth Fox, et al.
Pediatric Blood & Cancer|April 5, 2013
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium studyTrent R Hummel, Lars Wagner, Charlotte Ahern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2012
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium reportJulia Glade Bender, Susan M Blaney, Scott Borinstein, et al.
Pageof 5